BRIEF published on 04/15/2025 at 10:05, 1 year 2 months ago IOmx Therapeutics Gains Approval for IOMX-0675 Clinical Trials Immune Response IOmx Therapeutics IOMX-0675 Clinical Trial Approval Solid Tumor Therapy
BRIEF published on 04/15/2025 at 10:05, 1 year 2 months ago IOmx Therapeutics obtient l'approbation pour les essais cliniques sur IOMX-0675 Réponse Immunitaire IOmx Therapeutics IOMX-0675 Approbation Des Essais Cliniques Thérapie Des Tumeurs Solides
PRESS RELEASE published on 04/15/2025 at 10:00, 1 year 2 months ago iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675 iOmx Therapeutics receives regulatory approval for clinical trial application of IOMX-0675, a LILRB1/LILRB2 dual-targeting antibody, to reverse immune suppression in solid tumors Regulatory Approval Clinical Trial Application IOmx Therapeutics IOMX-0675 Solid Tumor
BRIEF published on 12/19/2024 at 14:05, 1 year 6 months ago IOmx Therapeutics Advances IOMX-0675 with Clinical Trial Application Cancer Treatment Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors
BRIEF published on 12/19/2024 at 14:05, 1 year 6 months ago IOmx Therapeutics fait progresser IOMX-0675 avec une application d'essai clinique Traitement Du Cancer Thérapeutique IOmx IOMX-0675 Demande D'essai Clinique Récepteurs Immunosuppresseurs
PRESS RELEASE published on 12/19/2024 at 14:00, 1 year 6 months ago iOmx Therapeutics submits Clinical Trial Application for IOMX-0675 iOmx Therapeutics submits Clinical Trial Application for IOMX-0675, a dual-targeting antibody demonstrating strong anti-tumor potential by reprogramming myeloid cells and restoring cytotoxic T cell function Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors Anti-tumor Potential
BRIEF published on 08/22/2024 at 10:05, 1 year 10 months ago IOmx Therapeutics Initiates Phase Ib with OMX-0407 Cancer Therapy Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 08/22/2024 at 10:05, 1 year 10 months ago IOmx Therapeutics lance la phase Ib avec OMX-0407 Essai Clinique Thérapie Contre Le Cancer OMX-0407 Phase Ib Thérapeutique IOmx
PRESS RELEASE published on 08/22/2024 at 10:00, 1 year 10 months ago iOmx Therapeutics Initiates Phase Ib with OMX-0407 iOmx Therapeutics initiates Phase Ib clinical trial with OMX-0407, showing favorable safety profile and anti-tumor activity in solid tumors. Expansion phase opens in kidney cancer and angiosarcoma Solid Tumors Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 06/27/2024 at 10:05, 2 years ago IOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer Chief Financial Officer Biopharmaceutical Leadership IOmx Therapeutics Florian Schmid
Published on 07/10/2026 at 15:00, 1 hour 38 minutes ago Mise à jour de l'entreprise First Canadian Graphite Inc Corporate Update
Published on 07/10/2026 at 14:20, 2 hours 18 minutes ago Giyani Announces Filing of Definitive Feasibility Study
Published on 07/10/2026 at 14:00, 2 hours 38 minutes ago Orogen Royalties Begins Trading on OTCQX Best Market
Published on 07/10/2026 at 13:30, 3 hours 8 minutes ago Empress Announces Acquisition of North American Royalty Portfolio
Published on 07/10/2026 at 15:39, 58 minutes ago Karsten Dümmler, founder and long-standing Chairman of the Management Board of Netfonds AG, is stepping down from the Supervisory Board at his own request
Published on 07/10/2026 at 15:26, 1 hour 12 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 07/10/2026 at 15:25, 1 hour 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: SEGRO plc
Published on 07/10/2026 at 15:24, 1 hour 14 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 07/10/2026 at 15:23, 1 hour 14 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 07/10/2026 at 10:34, 6 hours 4 minutes ago Nombre total d'actions et droits de vote - juin 2026
Published on 07/10/2026 at 10:34, 6 hours 4 minutes ago Number of shares and voting rights - June 2026 (In French only)
Published on 07/09/2026 at 18:48, 21 hours 50 minutes ago Information relative au nombre total des droits de vote et d’actions composant le capital social
Published on 07/09/2026 at 18:47, 21 hours 51 minutes ago ICADE - CP - Modification du contrat de liquidite au 01 juillet 2026
Published on 07/09/2026 at 18:39, 21 hours 59 minutes ago ICADE - CP - Bilan semestriel contrat de liquidité S1 2026
